Role of adrenoceptors in vitro and in vivo in the effects of lithium on blood glucose levels and insulin secretion in the rat.
1. Pretreatment of rats with the non-selective alpha-adrenoceptor antagonist dihydroergotamine counteracts the inhibition of glucose-induced insulin secretion caused by lithium both in vitro and in vivo. The present study was therefore carried out to specify further which type of adrenoceptor is involved in lithium-induced hyperglycaemia and inhibition of insulin secretion. 2. The lithium-induced effects were reversibly blocked by pretreatment of rats with the alpha 2-adrenoceptor antagonist yohimbine or a combination of yohimbine and the non-selective beta-receptor antagonist propranolol, whereas the alpha 1-receptor antagonist prazosin and propranolol alone were ineffective in blocking these effects. 3. These findings suggest that the effects of lithium on plasma glucose and insulin levels are mediated mainly by the stimulation of alpha 2-adrenoceptors.
Fontela
T
T
Centro de Investigaciones Biológicas, C.S.I.C., Madrid, Spain.
García Hermida
O
O
Gómez-Acebo
J
J
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D004087:Dihydroergotamine / Q000494:pharmacology; D005951:Glucose Tolerance Test; D066298:In Vitro Techniques; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism; D008094:Lithium / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011941:Receptors, Adrenergic / Q000378:metabolism / Q000502:physiology*; D013565:Sympatholytics / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D007328:Insulin; D011941:Receptors, Adrenergic; D013565:Sympatholytics; D015016:Yohimbine; D004087:Dihydroergotamine; D008094:Lithium